AnaptysBio Inc. (ANAB) and Cortexyme Inc. (NASDAQ:CRTX) Contrasting side by side

AnaptysBio Inc. (NASDAQ:ANAB) and Cortexyme Inc. (NASDAQ:CRTX) compete with each other in the Biotechnology sector. We will analyze and compare their analyst recommendations, profitability, risk, institutional ownership, dividends, earnings and valuation.

Earnings & Valuation

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
AnaptysBio Inc. 43 0.00 21.82M -2.68 0.00
Cortexyme Inc. 25 0.00 11.82M -4.34 0.00

Demonstrates AnaptysBio Inc. and Cortexyme Inc. earnings per share (EPS), top-line revenue and valuation.


Table 2 provides AnaptysBio Inc. and Cortexyme Inc.’s net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
AnaptysBio Inc. 50,427,547.95% -15.8% -15%
Cortexyme Inc. 46,886,156.29% 0% 0%


The Current Ratio and Quick Ratio of AnaptysBio Inc. are 17 and 17 respectively. Its competitor Cortexyme Inc.’s Current Ratio is 15.9 and its Quick Ratio is 15.9. AnaptysBio Inc. can pay off short and long-term obligations better than Cortexyme Inc.

Analyst Recommendations

The following table delivered below contains the ratings and recommendations for AnaptysBio Inc. and Cortexyme Inc.

Sell Ratings Hold Ratings Buy Ratings Rating Score
AnaptysBio Inc. 0 1 0 2.00
Cortexyme Inc. 0 0 0 0.00

$75 is AnaptysBio Inc.’s average price target while its potential upside is 112.83%.

Insider & Institutional Ownership

Institutional investors owned 0% of AnaptysBio Inc. shares and 22.4% of Cortexyme Inc. shares. AnaptysBio Inc.’s share owned by insiders are 0.2%. On the other hand, insiders owned about 2.5% of Cortexyme Inc.’s shares.


In this table we show the Weekly, Monthly, Quarterly, Half Yearly, Yearly and YTD Performance of both pretenders.

Performance (W) Performance (M) Performance (Q) Performance (HY) Performance (Y) Performance (YTD)
AnaptysBio Inc. -4.31% -2.7% -22.79% -17.79% -32.36% -15.8%
Cortexyme Inc. -13.66% -21.82% 0% 0% 0% 7.63%

For the past year AnaptysBio Inc. has -15.8% weaker performance while Cortexyme Inc. has 7.63% stronger performance.


AnaptysBio Inc. beats Cortexyme Inc. on 7 of the 10 factors.

AnaptysBio, Inc., a clinical stage biotechnology company, engages in developing antibody product candidates focused on unmet medical needs in inflammation. The companyÂ’s proprietary anti-inflammatory pipeline includes ANB020, an anti-interleukin-33 antibody for the treatment of moderate-to-severe adult atopic dermatitis, severe adult peanut allergy, and severe adult eosinophilic asthma; ANB019, an anti-interleukin-36R antibody for the treatment of rare inflammatory diseases, including generalized pustular psoriasis and palmo-plantar pustular psoriasis; and a portfolio of checkpoint receptor agonist antibodies for the treatment of certain autoimmune diseases. It also has an immuno-oncology partnership with TESARO, Inc. and TESARO Development, Inc. to develop and commercialize an anti-PD-1 antagonist antibody (TSR-042) and an anti-TIM-3 antagonist antibody (TSR-022), which are under clinical development; and an inflammation partnership with Celgene Corporation to develop an anti-PD-1 checkpoint agonist antibody (CC-90006) that is in clinical stage. The company was formerly known as Anaptys Biosciences, Inc. and changed its name to AnaptysBio, Inc. in July 2006. AnaptysBio, Inc. was founded in 2005 and is based in San Diego, California.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.